Carlos Alonso‐Moreno

Antibody-drug conjugate engineering: from design to efficacy and safety

Antibody–drug conjugates (ADCs) represent a rapidly expanding class of targeted cancer therapeutics that combine the high selectivity of monoclonal antibodies with the potent cytotoxic activity of small-molecule drugs. Their clinical success relies on the simultaneous optimizatio...